Goldman Sachs fancies Ferrari, Hermes, Novo Nordisk for European investors

Goldman analysts have advised European investors to favour growth stocks

Novo Nordisk shares have taken off following the success of its diabetes medications, Wegovy and Ozempic. Picture: Getty

European investors should tilt their portfolio to favour growth stocks, which should benefit from falling bond yields and faster economic growth next year, according to strategists at Goldman Sachs.

They’re bullish on a strategy called Pure Growth, a basket of stocks that includes healthcare companies along with Ferrari, Hermes International, Pernod Ricard, Novo Nordisk and Worldline.

“The fundamentals of growth stocks should stop underperforming and ...